{"entity":{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","aka":["PBAC","Pharmaceutical Benefits Scheme"],"tldr":"The independent committee that decides which medicines Australia's Pharmaceutical Benefits Scheme subsidises, and at what price, on cost-effectiveness evidence.","summary":"The PBAC is an independent expert body appointed by the Australian Government under the National Health Act 1953; no new medicine can be listed on the Pharmaceutical Benefits Scheme without a positive PBAC recommendation. It assesses comparative effectiveness and cost-effectiveness, publishes Public Summary Documents for every decision, and negotiates risk-sharing and managed-access arrangements for expensive cancer drugs with uncertain evidence. The PBS is one of the oldest universal medicines subsidy schemes and its rejections and deferrals of high-cost oncology drugs are closely watched by companies and patient groups. Registration by the TGA must precede or run in parallel with PBAC consideration.","asOf":"2026-09-09","links":[{"label":"PBAC","url":"https://www.pbs.gov.au/industry/listing/participants/pbac"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tga","cancer-council-australia","nice","peter-mac"],"pathways":[],"terms":["real-world-evidence","os"],"trials":[],"people":["robyn-ward"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Canberra","country":"AU","lat":-35.281,"lng":149.129,"institutionType":"government","website":"https://www.pbs.gov.au/industry/listing/participants/pbac","programs":["PBS listing recommendations","Public Summary Documents","Managed access and risk-sharing arrangements","Parallel TGA-PBAC process"]},"route":"/institutions/pbac/","neighbours":{"institution":[{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/"},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/"}],"term":[{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"person":[{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"idea":[{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/"}]}}